Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$4.81
+0.2%
$5.71
$1.38
$7.61
$80.04M1.2117,317 shs9,498 shs
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$2.20
+0.5%
$2.18
$1.98
$4.48
$100.56M0.5393,554 shs2,463 shs
Liquidia Co. stock logo
LQDA
Liquidia
$12.41
+0.3%
$14.55
$5.71
$16.99
$943.53M0.16944,306 shs110,882 shs
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$0.06
+12.7%
$0.08
$0.05
$1.25
$2.58M-0.0680,769 shs779 shs
PolyPid Ltd. stock logo
PYPD
PolyPid
$4.90
+1.9%
$5.05
$3.57
$13.50
$23.52M1.416,367 shs202 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-4.57%+0.21%-11.93%-19.06%+210.68%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-0.45%+6.31%+1.86%+3.79%-47.10%
Liquidia Co. stock logo
LQDA
Liquidia
-1.43%-10.43%-22.30%+1.64%+82.99%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-12.78%-28.96%-33.10%-38.65%-92.69%
PolyPid Ltd. stock logo
PYPD
PolyPid
+6.42%+11.86%-0.62%-26.56%-63.18%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BrainsWay Ltd. stock logo
BWAY
BrainsWay
1.6766 of 5 stars
3.33.00.00.01.70.80.6
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
1.3628 of 5 stars
3.51.00.00.00.62.50.6
Liquidia Co. stock logo
LQDA
Liquidia
2.2435 of 5 stars
3.31.00.00.02.14.20.6
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
2.3183 of 5 stars
3.50.00.04.50.01.70.0
PolyPid Ltd. stock logo
PYPD
PolyPid
1.0518 of 5 stars
0.05.00.00.02.41.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BrainsWay Ltd. stock logo
BWAY
BrainsWay
2.67
Moderate Buy$7.0045.53% Upside
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
3.00
Buy$3.5059.09% Upside
Liquidia Co. stock logo
LQDA
Liquidia
2.60
Moderate Buy$21.0069.22% Upside
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3.00
Buy$2.503,812.36% Upside
PolyPid Ltd. stock logo
PYPD
PolyPid
3.00
BuyN/AN/A

Current Analyst Ratings

Latest LQDA, PYPD, KRMD, NMRD, and BWAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
4/1/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/14/2024
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/14/2024
Liquidia Co. stock logo
LQDA
Liquidia
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $32.00
3/13/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
3/11/2024
BrainsWay Ltd. stock logo
BWAY
BrainsWay
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
2/21/2024
Liquidia Co. stock logo
LQDA
Liquidia
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BrainsWay Ltd. stock logo
BWAY
BrainsWay
$31.78M2.52N/AN/A$2.50 per share1.92
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
$28.52M3.53N/AN/A$0.45 per share4.89
Liquidia Co. stock logo
LQDA
Liquidia
$17.49M53.95N/AN/A$0.73 per share17.00
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
$80K32.23N/AN/A($0.41) per share-0.16
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/A($1.27) per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$4.20M-$0.13N/A60.13N/A-13.20%-10.05%-6.88%5/8/2024 (Confirmed)
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$13.74M-$0.29N/AN/AN/A-48.18%-27.82%-21.30%5/1/2024 (Confirmed)
Liquidia Co. stock logo
LQDA
Liquidia
-$78.50M-$1.20N/AN/AN/A-448.89%-132.16%-65.35%5/2/2024 (Estimated)
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
-$14.14M-$0.39N/AN/AN/AN/A-142.69%N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$23.86M-$19.68N/AN/AN/AN/A-450.37%-101.27%5/8/2024 (Confirmed)

Latest LQDA, PYPD, KRMD, NMRD, and BWAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2024N/A
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.02N/A+$0.02N/AN/AN/A  
5/8/2024N/A
PolyPid Ltd. stock logo
PYPD
PolyPid
-$1.96N/A+$1.96N/AN/AN/A  
5/1/2024N/A
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04N/A+$0.04N/AN/AN/A  
3/13/2024Q4 2023
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
-$0.04-$0.02+$0.02$0.12$7.01 million$7.19 million
3/13/2024Q4 2023
Liquidia Co. stock logo
LQDA
Liquidia
-$0.23-$0.42-$0.19-$0.42$5.29 million$4.53 million
3/6/202412/31/2023
BrainsWay Ltd. stock logo
BWAY
BrainsWay
-$0.03-$0.01+$0.02N/A$8.40 million$9.03 million    
2/14/2024Q4 2023
PolyPid Ltd. stock logo
PYPD
PolyPid
-$2.17-$3.97-$1.80-$3.97N/AN/A
2/12/2024Q3 2024
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A-$0.12-$0.12-$0.17N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/AN/AN/AN/AN/A
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
N/AN/AN/AN/AN/A
Liquidia Co. stock logo
LQDA
Liquidia
N/AN/AN/AN/AN/A
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/AN/AN/AN/AN/A
PolyPid Ltd. stock logo
PYPD
PolyPid
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BrainsWay Ltd. stock logo
BWAY
BrainsWay
N/A
5.68
5.30
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
0.02
4.55
3.77
Liquidia Co. stock logo
LQDA
Liquidia
N/A
4.85
4.85
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
N/A
0.19
0.03
PolyPid Ltd. stock logo
PYPD
PolyPid
2.17
0.83
0.83

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
30.11%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
58.60%
Liquidia Co. stock logo
LQDA
Liquidia
64.54%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
4.41%
PolyPid Ltd. stock logo
PYPD
PolyPid
26.47%

Insider Ownership

CompanyInsider Ownership
BrainsWay Ltd. stock logo
BWAY
BrainsWay
19.00%
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
25.60%
Liquidia Co. stock logo
LQDA
Liquidia
31.60%
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
41.60%
PolyPid Ltd. stock logo
PYPD
PolyPid
24.70%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BrainsWay Ltd. stock logo
BWAY
BrainsWay
13416.64 million13.48 millionNot Optionable
KORU Medical Systems, Inc. stock logo
KRMD
KORU Medical Systems
8245.71 million34.01 millionOptionable
Liquidia Co. stock logo
LQDA
Liquidia
14576.03 million52.00 millionOptionable
Nemaura Medical Inc. stock logo
NMRD
Nemaura Medical
3640.35 million23.57 millionOptionable
PolyPid Ltd. stock logo
PYPD
PolyPid
594.80 million3.61 millionNo Data

LQDA, PYPD, KRMD, NMRD, and BWAY Headlines

SourceHeadline
PYPD: Polypid is Enhancing Surgical OutcomesPYPD: Polypid is Enhancing Surgical Outcomes
msn.com - April 24 at 11:46 AM
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
globenewswire.com - April 24 at 7:00 AM
PolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo FinancePolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - April 18 at 12:39 PM
PolyPid to Participate in Barclays 26th Annual Global Healthcare ConferencePolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
globenewswire.com - February 28 at 7:00 AM
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
finance.yahoo.com - February 19 at 6:10 PM
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com - February 19 at 1:00 PM
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 15 at 11:57 AM
Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning
markets.businessinsider.com - February 14 at 5:44 PM
PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsPolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - February 14 at 12:44 PM
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
finance.yahoo.com - February 14 at 7:32 AM
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - February 14 at 7:00 AM
PolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialPolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
finanznachrichten.de - February 12 at 7:54 AM
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
finance.yahoo.com - February 12 at 7:54 AM
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
finance.yahoo.com - January 31 at 10:35 AM
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Fridays Mid-Day SessionWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
msn.com - January 5 at 3:33 PM
Cyclacel Pharmaceuticals, Angiodynamic among healthcare moversCyclacel Pharmaceuticals, Angiodynamic among healthcare movers
msn.com - January 5 at 10:29 AM
PolyPid Ltd. (PYPD)PolyPid Ltd. (PYPD)
uk.finance.yahoo.com - January 4 at 6:14 PM
PolyPid looks to raise $16.2M through private placementPolyPid looks to raise $16.2M through private placement
msn.com - January 4 at 6:14 PM
PolyPid Announces Private Placement for $16 Million in Gross ProceedsPolyPid Announces Private Placement for $16 Million in Gross Proceeds
finance.yahoo.com - January 4 at 6:14 PM
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 12 at 1:15 PM
Earnings call: PolyPids Q3 2023 financial results show decreased expenses and progress in SHIELD II trialEarnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trial
investing.com - November 12 at 8:15 AM
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 8:16 AM
PolyPids Earnings: A PreviewPolyPid's Earnings: A Preview
benzinga.com - November 7 at 5:14 PM
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsPolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
finance.yahoo.com - November 7 at 7:12 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BrainsWay logo

BrainsWay

NASDAQ:BWAY
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
KORU Medical Systems logo

KORU Medical Systems

NASDAQ:KRMD
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Liquidia logo

Liquidia

NASDAQ:LQDA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Nemaura Medical logo

Nemaura Medical

NASDAQ:NMRD
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
PolyPid logo

PolyPid

NASDAQ:PYPD
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.